RU2015137815A - Биодеградируемые и клинически совместимые наночастицы в качестве носителей для доставки лекарственного средства - Google Patents
Биодеградируемые и клинически совместимые наночастицы в качестве носителей для доставки лекарственного средства Download PDFInfo
- Publication number
- RU2015137815A RU2015137815A RU2015137815A RU2015137815A RU2015137815A RU 2015137815 A RU2015137815 A RU 2015137815A RU 2015137815 A RU2015137815 A RU 2015137815A RU 2015137815 A RU2015137815 A RU 2015137815A RU 2015137815 A RU2015137815 A RU 2015137815A
- Authority
- RU
- Russia
- Prior art keywords
- nanoparticle
- core
- peptide
- protein
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Ceramic Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361761012P | 2013-02-05 | 2013-02-05 | |
| US61/761,012 | 2013-02-05 | ||
| PCT/US2014/014751 WO2014123935A1 (en) | 2013-02-05 | 2014-02-05 | Biodegradable and clinically-compatible nanop articles as drug delivery carriers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015137815A true RU2015137815A (ru) | 2017-03-13 |
Family
ID=51300093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015137815A RU2015137815A (ru) | 2013-02-05 | 2014-02-05 | Биодеградируемые и клинически совместимые наночастицы в качестве носителей для доставки лекарственного средства |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11001840B2 (https=) |
| EP (2) | EP3845248A1 (https=) |
| JP (1) | JP6507102B2 (https=) |
| KR (1) | KR20150132131A (https=) |
| AU (2) | AU2014215421A1 (https=) |
| CA (1) | CA2899155A1 (https=) |
| ES (1) | ES2873600T3 (https=) |
| IL (1) | IL240148A0 (https=) |
| MX (1) | MX2015010083A (https=) |
| RU (1) | RU2015137815A (https=) |
| SG (2) | SG10201706968UA (https=) |
| WO (1) | WO2014123935A1 (https=) |
| ZA (1) | ZA201506530B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3845248A1 (en) | 2013-02-05 | 2021-07-07 | 1Globe Health Institute LLC | Biodegradable and clinically-compatible nanoparticles as drug delivery carriers |
| CN105579582A (zh) | 2013-07-25 | 2016-05-11 | 埃克西奎雷股份有限公司 | 用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体 |
| AU2015269412B2 (en) | 2014-06-04 | 2020-03-12 | Exicure Operating Company | Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications |
| WO2016028940A1 (en) | 2014-08-19 | 2016-02-25 | Northwestern University | Protein/oligonucleotide core-shell nanoparticle therapeutics |
| KR20170078843A (ko) | 2014-11-21 | 2017-07-07 | 노오쓰웨스턴 유니버시티 | 구형 핵산 나노입자 접합체의 서열 특이적 세포 흡수 |
| WO2016115320A1 (en) | 2015-01-14 | 2016-07-21 | Exicure, Inc. | Nucleic acid nanostructructures with core motifs |
| EP3452598A4 (en) | 2016-05-06 | 2020-04-29 | Exicure, Inc. | LIPOSOMAL SPHERICAL NUCLEIC ACID (ANS) CONSTRUCTS HAVING ANTISENSE OLIGONUCLEOTIDES (ASO) FOR THE SPECIFIC INACTIVATION OF INTERLEUKIN 17 RECEPTOR RNA |
| US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| US10800817B2 (en) * | 2016-12-19 | 2020-10-13 | Morehouse School Of Medicine | Compositions and methods for treating diseases by inhibiting exosome release |
| PL3568122T3 (pl) * | 2017-01-10 | 2024-03-18 | Dukebox Sp. Z O.O. | Sposób wytwarzania zawiesiny nanocząsteczek soli potasowej albo soli magnezowej |
| US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
| WO2018209270A1 (en) | 2017-05-11 | 2018-11-15 | Northwestern University | Adoptive cell therapy using spherical nucleic acids (snas) |
| KR102120482B1 (ko) * | 2018-10-05 | 2020-06-08 | 씨제이제일제당 (주) | 생분해성 고분자 나노입자를 포함하는 메모리 소자 및 이의 제조방법 |
| WO2021011398A1 (en) * | 2019-07-12 | 2021-01-21 | The Board Of Trustees Of The Leland Stanford Junior University | Functionalized nanoparticles and their use in treating bacterial infections |
| WO2021067952A1 (en) * | 2019-10-04 | 2021-04-08 | The University Of Chicago | Targeted nanomedicine for treating vascular disorders |
| US20230070049A1 (en) * | 2020-02-03 | 2023-03-09 | Rutgers, The State University Of New Jersey | Microrna-7 compositions for promoting functional recovery following spinal cord injury and methods of use thereof |
| US11998615B2 (en) | 2021-04-14 | 2024-06-04 | The Board Of Trustees Of The Leland Stanford Junior University | Functionalized nanoparticles and their use in treating bacterial infections |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5219577A (en) | 1990-06-22 | 1993-06-15 | The Regents Of The University Of California | Biologically active composition having a nanocrystalline core |
| TW406020B (en) * | 1993-09-29 | 2000-09-21 | Bristol Myers Squibb Co | Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent |
| US5879715A (en) * | 1997-09-02 | 1999-03-09 | Ceramem Corporation | Process and system for production of inorganic nanoparticles |
| DE19856432A1 (de) * | 1998-12-08 | 2000-06-15 | Basf Ag | Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen |
| DE19912502A1 (de) | 1999-03-19 | 2000-09-21 | Inst Neue Mat Gemein Gmbh | Nanoskalige Teilchen, Komplexe mit Polynukleotiden und deren Verwendung |
| AU2002214854A1 (en) | 2000-10-25 | 2002-05-06 | Inex Pharmaceuticals Corporation | Lipid formulations for target delivery |
| IN192520B (https=) * | 2001-08-01 | 2004-04-24 | Univ Delhi | |
| ES2559828T3 (es) | 2003-07-16 | 2016-02-16 | Protiva Biotherapeutics Inc. | ARN de interferencia encapsulado en lípidos |
| JP5103022B2 (ja) | 2004-02-13 | 2012-12-19 | ノッド ファーマシューティカルズ， インコーポレイテッド | リン酸カルシウムナノ粒子のコア、生体分子および胆汁酸を含む粒子、ならびにそれらの製造方法および治療用途 |
| US7611690B2 (en) | 2005-01-04 | 2009-11-03 | Gp Medical, Inc. | Nanoparticles for protein drug delivery |
| US20110081410A1 (en) | 2005-06-28 | 2011-04-07 | St. Marianna University, School Ofmedicine | Therapeutic agent for local inflammation |
| CN100435784C (zh) | 2005-07-25 | 2008-11-26 | 管晓虹 | 含有和包封中药成分的无机盐纳米粒子的制备方法 |
| US20080248108A1 (en) * | 2006-10-06 | 2008-10-09 | Jain Krotz | Multilayered polyelectrolyte-based capsules for cell encapsulation and delivery of therapeutic compositions |
| CN101686939B (zh) | 2007-04-17 | 2013-03-27 | 巴克斯特国际公司 | 用于肺部投送的核酸微粒 |
| WO2009012303A2 (en) * | 2007-07-16 | 2009-01-22 | Northeastern University | Therapeutic stable nanoparticles |
| JP2010537640A (ja) * | 2007-08-27 | 2010-12-09 | ボストン バイオメディカル， インコーポレイテッド | マイクロｒｎａ模倣剤または阻害剤としての非対称性ｒｎａ二重鎖の組成物 |
| WO2009042625A1 (en) | 2007-09-25 | 2009-04-02 | Idexx Laboratories, Inc. | Pharmaceutical compositions for administering oligonucleotides |
| CA2707010A1 (en) | 2007-12-14 | 2009-06-25 | Kazuhisa Sugimoto | .alpha.-lipoic acid nanoparticles and methods for preparing thereof |
| CA2710983A1 (en) | 2007-12-27 | 2009-10-01 | The Ohio State University Research Foundation | Lipid nanoparticle compositions and methods of making and using the same |
| WO2009140421A2 (en) | 2008-05-13 | 2009-11-19 | University Of Washington | Polymeric carrier |
| JP2012509904A (ja) | 2008-11-26 | 2012-04-26 | ユニバーシティ・オブ・カンザス | 核酸送達組成物および核酸送達法 |
| EP2198885B1 (en) | 2008-12-19 | 2012-02-08 | Biolitec AG | Calcium phosphate nanoparticles as dye carrier for photodynamic therapy |
| US9937128B2 (en) * | 2009-08-03 | 2018-04-10 | The University Of North Carolina At Chapel Hill | Liposomes comprising a calcium phosphate-containing precipitate |
| US20120220647A1 (en) * | 2009-09-14 | 2012-08-30 | Jin-Ho Choy | Nano-hybrid of targetable sirna-layered inorganic hydroxide, manufacturing method thereof, and pharmaceutical composition for treating tumor comprising the nano-hybrid |
| JP5491119B2 (ja) * | 2009-10-02 | 2014-05-14 | 日東電工株式会社 | 薬物含有微粒子を含む医薬組成物およびその製造方法 |
| US20130236396A1 (en) * | 2010-05-03 | 2013-09-12 | University Of Utah Research Foundation | Nanoparticles produced from recombinant polymers and methods of making and using the same |
| WO2013040295A2 (en) | 2011-09-14 | 2013-03-21 | University Of South Florida | Divalent-metal coated nanoparticles for delivery of compositions into the central nervous system by nasal insufflation |
| CA2853685C (en) | 2011-11-04 | 2019-09-03 | Nitto Denko Corporation | Single use system for sterilely producing lipid-nucleic acid particles |
| US20130243699A1 (en) | 2011-12-07 | 2013-09-19 | Regents Of The University Of Minnesota | Biodegradable Magnetic Nanoparticles and Related Methods |
| ITRM20120480A1 (it) | 2012-10-09 | 2014-04-10 | Uni Degli Studi Camerino | Nanoparticelle lipidiche multicomponenti e procedimenti per la loro preparazione. |
| EP3845248A1 (en) | 2013-02-05 | 2021-07-07 | 1Globe Health Institute LLC | Biodegradable and clinically-compatible nanoparticles as drug delivery carriers |
-
2014
- 2014-02-05 EP EP20204049.9A patent/EP3845248A1/en active Pending
- 2014-02-05 SG SG10201706968UA patent/SG10201706968UA/en unknown
- 2014-02-05 AU AU2014215421A patent/AU2014215421A1/en not_active Abandoned
- 2014-02-05 RU RU2015137815A patent/RU2015137815A/ru not_active Application Discontinuation
- 2014-02-05 MX MX2015010083A patent/MX2015010083A/es unknown
- 2014-02-05 CA CA2899155A patent/CA2899155A1/en not_active Abandoned
- 2014-02-05 ES ES14748796T patent/ES2873600T3/es active Active
- 2014-02-05 WO PCT/US2014/014751 patent/WO2014123935A1/en not_active Ceased
- 2014-02-05 EP EP14748796.1A patent/EP2953646B1/en active Active
- 2014-02-05 SG SG11201506116XA patent/SG11201506116XA/en unknown
- 2014-02-05 JP JP2015556243A patent/JP6507102B2/ja active Active
- 2014-02-05 KR KR1020157024176A patent/KR20150132131A/ko not_active Withdrawn
- 2014-02-05 US US14/765,763 patent/US11001840B2/en active Active
-
2015
- 2015-07-26 IL IL240148A patent/IL240148A0/en unknown
- 2015-09-04 ZA ZA2015/06530A patent/ZA201506530B/en unknown
-
2018
- 2018-02-07 AU AU2018200903A patent/AU2018200903A1/en not_active Abandoned
-
2021
- 2021-04-06 US US17/223,647 patent/US20210230595A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160046936A1 (en) | 2016-02-18 |
| AU2014215421A1 (en) | 2015-08-13 |
| EP2953646A4 (en) | 2017-02-15 |
| IL240148A0 (en) | 2015-09-24 |
| AU2018200903A1 (en) | 2018-02-22 |
| ES2873600T3 (es) | 2021-11-03 |
| EP2953646A1 (en) | 2015-12-16 |
| EP2953646B1 (en) | 2021-03-10 |
| US20210230595A1 (en) | 2021-07-29 |
| SG11201506116XA (en) | 2015-09-29 |
| HK1217906A1 (en) | 2017-01-27 |
| WO2014123935A9 (en) | 2014-10-23 |
| CA2899155A1 (en) | 2014-08-14 |
| EP3845248A1 (en) | 2021-07-07 |
| MX2015010083A (es) | 2016-04-26 |
| KR20150132131A (ko) | 2015-11-25 |
| WO2014123935A1 (en) | 2014-08-14 |
| ZA201506530B (en) | 2018-11-28 |
| SG10201706968UA (en) | 2017-09-28 |
| US11001840B2 (en) | 2021-05-11 |
| JP2016513090A (ja) | 2016-05-12 |
| JP6507102B2 (ja) | 2019-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015137815A (ru) | Биодеградируемые и клинически совместимые наночастицы в качестве носителей для доставки лекарственного средства | |
| JP2016513090A5 (https=) | ||
| Sun et al. | Leveraging physiology for precision drug delivery | |
| CN106793970B (zh) | 用于诊断及治疗的纳米载剂及其加工 | |
| Agrahari et al. | Nanocarrier fabrication and macromolecule drug delivery: challenges and opportunities | |
| Pan et al. | Nanoparticles: promising tools for the treatment and prevention of myocardial infarction | |
| McMasters et al. | Delivery of anti-inflammatory peptides from hollow PEGylated poly (NIPAM) nanoparticles reduces inflammation in an ex vivo osteoarthritis model | |
| US11850309B2 (en) | Cationic materials and formulations for drug delivery | |
| Li et al. | Multiple delivery strategies of nanocarriers for myocardial ischemia-reperfusion injury: current strategies and future prospective | |
| KR20140138639A (ko) | 점막 침투 강화를 나타내는 나노 입자 제형 | |
| Pascual-Gil et al. | Tracking the in vivo release of bioactive NRG from PLGA and PEG–PLGA microparticles in infarcted hearts | |
| Xie et al. | A novel therapeutic outlook: Classification, applications and challenges of inhalable micron/nanoparticle drug delivery systems in lung cancer | |
| US20190321305A1 (en) | Polymeric nanoparticles | |
| Yan et al. | Elaboration a ROS-responsive darutigenol prodrug nanoassemblies for inflammatory arthritis treatment | |
| CN111107842B (zh) | 利用微混合和卡培他滨两亲性特性的卡培他滨的聚合物-脂质混杂纳米颗粒 | |
| Zhang et al. | Development and advantages of drug delivery systems | |
| US10632080B2 (en) | Compositions and methods to improve nanoparticle distribution within the brain interstitium | |
| Ulku et al. | The importance of nanotechnology and drug carrier systems in pharmacology | |
| WO2014044894A1 (es) | Formulación de liberación controlada | |
| WO2012094512A2 (en) | Myocardial tissue targeting peptides | |
| Lakshmi | A Review on Nanoformulations Targeting Brain Drug Delivery. | |
| Gohil et al. | Nanocarriers in protein and peptide drug delivery | |
| Chen et al. | Cartilage targeting function in the drug delivery system by intra-articular injection for the treatment of osteoarthritis | |
| US12465569B2 (en) | Microparticle formulations for intravenous therapy and methods for their manufacture and use | |
| Qaiser et al. | Nanotechnology: A New Hope for the Cure of Osteoarthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20181126 |